Business Insights, July 2002
market means that pharmaceutical executives need to keep up-to-date on current and future market developments. The CNSOutlook to 2007 provides an analysis of the 2001 performance in the major CNS markets
Business Insights, Oct 2005
'The CNS Market Outlook to 2010' provides detailed analysis on 7 key indications in the CNS Market, identifying growth brands, leading companies and epidemiology and product sales forecasts over the period
Business Insights, Feb 2004, Pages: 164
The Outlook for Niche CNS Disorders: Commercial opportunities in developing markets, evaluates the market and pipeline dynamics of five conditions; narcolepsy, Tourette's syndrome (TS), Huntington
Bizacumen Inc., Nov 2009, Pages: 305
While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes with potential to stop or reverse the disease's progression
Decision Resources, Inc., May 2008, Pages: 38
treatment; current medical practice for psychiatric indications.
- Current and emerging diagnostic technologies for psychiatric indications: EEG (Aspect Medical Systems, CNS Response, Memory Pharmaceuticals
Industry Experts, July 2010, Pages: 216
in this study include Stem Cell Transplants, Cell Based Genomics, Xenotransplants and Other. The report also analyzes the market for hESC therapeutic areas including Central Nervous System (CNS), Tissue
Decision Resources, Inc., Dec 2006, Pages: 25
of the body that are incapable of autonomous healing, such as the central nervous system (CNS). How can stem cells boost healing in the CNS? What are the limitations of these therapies in the CNS? What
Espicom Business Intelligence Ltd, June 2010, Pages: 70
of diseases of the central nervous system (CNS). To date, the company has largely focused on drugs for psychiatry and neurology, however it has broader ambitions, namely to become one of the world’s leading
Select Biosciences Ltd, Feb 2009, Pages: 310
for apoptosis modulators in indications such as CNS disorders and chronic inflammation/autoimmunity are also explored.
Key Features
- Examination of the molecular events in apoptosis which may become
Datamonitor, Dec 2010, Pages: 79
and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Baxter's strategic outlook across the next 6 years
Business Insights, Oct 2006, Pages: 199
portfolios, stronger late-stage drug development capabilities, M&A and in-licensing activity. ‘The Specialty Pharma Market Outlook ’evaluates current specialty pharma models, financial performance, core
Espicom Business Intelligence Ltd, Jan 2010, Pages: 84
, principally Cardiovascular; Oncology/ Infection; Gastrointestinal; Central Nervous System (CNS); Inflammation/Allergy; and Diabetes. In the future, DSP intends to focus its product base on CNS diseases
GBI Research, Feb 2010, Pages: 85
in terms of the LCM pipeline.
- Insight into the LCM activities in the top five therapeutic areas including cancer, central nervous system (CNS), cardiovascular system (CVS), metabolic diseases
Business Insights, July 2011, Pages: 97
for medical nutrition
Development, regulation and reimbursement
Future market outlook
About the authors
Sara Sleigh
Cheryl L Barton
Disclaimer
Introduction
Summary
Medical nutrition: a definition
Espicom Business Intelligence Ltd, Jan 2010, Pages: 82
UCB is a global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of CNS disorders, allergy
Decision Resources, Inc., July 2008, Pages: 86
Drugs for disorders of the central nervous system (CNS) form the second-ranked therapeutic area in terms of global pharmaceutical sales, reaching total retail sales in 2006 of $73.4 billion
Business Insights, May 2006, Pages: 199
, respiratory, anti-infectives and CNS disorders across the 8 largest EU Accession markets?
- How significant is the threat on branded products from the growth of the generics market?
- What are the key
Business Insights, April 2008, Pages: 265
Mycobacteria
MRSA
Sepsis screening
Biomarkers in CNS disorders
Alzheimer's disease
Other neurodegenerative disorders
Multiple sclerosis
Traumatic brain injury
Biomarkers of CNS drug efficacy
Biomarkers
Takeda Pacific, Feb 2010, Pages: 144
, applications, M&As, alliances, tools & technologies, products and R&D services. This report provides a detailed outlook of the market for biomarkers and related genomic, proteomic, or other tests used in drug R
Datamonitor, Dec 2010, Pages: 58
and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Lundbeck's strategic outlook across the next 6 years
